RecruitingPhase 2NCT05028829

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

Multi-center Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Long-term Atorvastatin (20 mg/Day) v. Placebo on HCC Risk in Individuals With Advanced Liver Fibrosis

Sponsor

Raymond Chung

Enrollment

60 participants

Start Date

May 10, 2023

Study Type

INTERVENTIONAL

Conditions

Cirrhosis Liver Fibroses

Summary

Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atorvastatin 20mg and a drug called Placebo for people with cirrhosis and liver fibroses. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.